- $701.80m
- $461.67m
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Sagimet Biosciences Q2 net loss widens on higher R&D costs
Brief: Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates
Sagimet Biosciences Q1 net loss narrows as R&D costs fall
Brief: Sagimet Biosciences Offers 29.17 Million Shares Of Series A Common Stock - SEC Filing
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall
Brief: Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks
Brief: Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat
Sagimet Biosciences Q3 net loss narrows as costs drop
Brief: Positive Phase 3 Results For Denifanstat For The Treatment Of Moderate To Severe Acne To Be Presented At The Eadv Congress 2025 By Partner Ascletis
Sagimet Biosciences Inc expected to post a loss of 51 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-TransMedics, Centrus Energy, MongoDB
U.S. STOCKS ON THE MOVE-Boeing, GlobalFoundries, Tesla
U.S. STOCKS ON THE MOVE-Merus NV, Copper miners, GlobalFoundries
U.S. STOCKS ON THE MOVE-Trevi Therapeutics, Cactus, Copper miners
Brief: Sagimet Biosciences Announces Positive Phase 3 Results For Denifanstat